0.54Open0.54Pre Close0 Volume2 Open Interest125.00Strike Price0.00Turnover172.28%IV26.95%PremiumJul 5, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.54Extrinsic Value100Contract SizeAmericanOptions Type-0.0394Delta0.0027Gamma315.50Leverage Ratio-0.2784Theta-0.0008Rho-12.43Eff Leverage0.0157Vega
AbbVie Stock Discussion
EPKINLY (Epcoritamab) Now Approved for Patients w/ Follicular Lymphoma (FL)
» Positive results in Ph1/2 EPCORE® NHL-1 study for R/R FL
» Offers off-the-shelf T-cell therapy
» First-of-its-kind antibody for both R/R FL & DLBCL after prior treatments (2+ lines)
One of the U.S.’s largest energy corporations, Chevron Corporation (NYSE:CVX) specializes in oil, gas and renewable fuels. The company has upstream and downstream operations focused on the oil and gas industry. Oil companies are an interesting pick since the best ones are known for paying dividends, even in bad times.
Chevron has a 37-year history of increasing dividends and has consistently paid them since ...
$Merck & Co(MRK.US)$ $Bristol-Myers Squibb(BMY.US)$ $Johnson & Johnson(JNJ.US)$ $Pfizer(PFE.US)$ $Novo-Nordisk A/S(NVO.US)$ $AbbVie(ABBV.US)$
$AbbVie(ABBV.US)$ +189%
$Bristol-Myers Squibb(BMY.US)$ +175%
$Johnson & Johnson(JNJ.US)$ +95%
$AstraZeneca(AZN.US)$ +78%
$NVM +45%
$Merck & Co(MRK.US)$ +37%
$ROCHE HOLDING AG(RHHBY.US)$ +27%
$Pfizer(PFE.US)$ +13%
$GlaxoSmithKline(GSK.US)$ +13%
----- $SPDR S&P 500 ETF(SPY.US)$ +12% -----
$Sanofi(SNY.US)$ +3%
Source: Arjun Murthy on the HR app!
Recently, there have been signs that World War 3
In light of this hypothetical situation
Who are the winners?
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US)$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
$MRTX
Acquired By: Bristol-Myers Squibb $Bristol-Myers Squibb(BMY.US)$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US)$ $GlaxoSmithKline(GSK.US)$
No comment yet